Eurofins reported first-half organic sales growth of 2.7%, with adjusted EBITDA margin expanding to 23.7% from 22.4% year over year. Management maintained its guidance. Shares are down 7% intraday July 23.
There are still sufficient acquisition targets left for Eurofins in its growth markets, allowing it to have continuous high growth while fortifying its competitive positioning through its hub-and-spoke network.
Eurofins has achieved leading positions in key markets primarily through acquisitions. In the future, Eurofins may overpay on acquisitions to meet top-line targets.
|
Metric
|
ERF
|
CRL
|
SGSN
|
|---|---|---|---|
Price/Earnings (Normalized) | 19.15 | 28.66 | 25.42 |
Price/Book Value | 3.36 | 4.82 | 18.34 |
Price/Sales | 1.74 | 3.50 | 2.54 |
Price/Cash Flow | 9.81 | 20.39 | 15.37 |
|
Metric
|
ERF
|
CRL
|
SGSN
|
|---|---|---|---|
Quick Ratio | 0.87 | 0.80 | 0.93 |
Current Ratio | 1.13 | 1.35 | 0.95 |
Interest Coverage | 5.15 | −0.77 | 11.63 |
|
Metric
|
ERF
|
CRL
|
SGSN
|
|---|---|---|---|
Return on Assets (Normalized) | 6.96% | 6.50% | 9.61% |
Return on Equity (Normalized) | 21.47% | 15.51% | 88.73% |
Return on Invested Capital (Normalized) | 9.71% | 9.46% | 13.55% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|cRj@T^? | LOCK|%r | $216B | |||
| Danaher Corp
DHR
| LOCK|P&Lj<T? | LOCK|$! | $142B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|v&vT@># | LOCK|m% | $43B | |||
| Agilent Technologies Inc
A
| LOCK|ctZbzr&h | LOCK|?! | $42B | |||
| Waters Corp
WAT
| LOCK|Mp<#b%< | LOCK|MPy | $40B | |||
| IQVIA Holdings Inc
IQV
| LOCK|!<r$?% | LOCK|<?@DH | $40B | |||
| Illumina Inc
ILMN
| LOCK|!c$@!x | LOCK|>t?> | $29B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|lq&>w#r | LOCK|L&GFn | $28B | |||
| Labcorp Holdings Inc
LH
| LOCK|%n?Hy&bn | LOCK|rpg# | $26B | |||
| Quest Diagnostics Inc
DGX
| LOCK|wyGXrC | LOCK|sGm<& | $26B |
United States